The landscape in medtech investing is changing, and one need only look at two signposts to see that this is so: the exit values of VC-backed companies over the past eight years (lower than anticipated), and the amount of time required to achieve those exits (longer than ever before). De Novo Ventures' Richard Ferrari presents the trends that emerge from eight years of venture investing in medical technology companies.
by Richard M. Ferrari
Over the last four years the amount of capital flowing into the health care sector has remained robust—in fact, it’s at an all time high, and that has many venture...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.
Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now
Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.
CEO Matt Gline talked to Scrip in an interview about dealmaking and the road back to commercialization.
Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.
CEO Matt Gline talked to Scrip in an interview about dealmaking and the road back to commercialization.
Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.
